Genetic architecture of human fibrotic diseases: disease risk and disease progression
Genetic studies of human diseases have identified multiple genetic risk loci for various fibrotic diseases. This has provided insights into the myriad of biological pathways potentially involved in disease pathogenesis. These discoveries suggest that alterations in immune responses, barrier function...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Frontiers Media S.A.,
2013-12-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1dfd4519c022478b94e3b3e70da8965d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Agnès eGardet |e author |
| 700 | 1 | 0 | |a Timothy S Zheng |e author |
| 700 | 1 | 0 | |a Joanne L Viney |e author |
| 245 | 0 | 0 | |a Genetic architecture of human fibrotic diseases: disease risk and disease progression |
| 260 | |b Frontiers Media S.A., |c 2013-12-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2013.00159 | ||
| 520 | |a Genetic studies of human diseases have identified multiple genetic risk loci for various fibrotic diseases. This has provided insights into the myriad of biological pathways potentially involved in disease pathogenesis. These discoveries suggest that alterations in immune responses, barrier function, metabolism and telomerase activity may be implicated in the genetic risks for fibrotic diseases. In addition to genetic disease-risks, the identification of genetic disease-modifiers associated with disease complications, severity or prognosis provides crucial insights into the biological processes implicated in disease progression. Understanding the biological processes driving disease progression may be critical to delineate more effective strategies for therapeutic interventions. This review provides an overview of current knowledge and gaps regarding genetic disease-risks and genetic disease-modifiers in human fibrotic diseases. | ||
| 546 | |a EN | ||
| 690 | |a Fibrosis | ||
| 690 | |a Genetics | ||
| 690 | |a GWAS | ||
| 690 | |a disease progression | ||
| 690 | |a auto-immunity | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 4 (2013) | |
| 787 | 0 | |n http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00159/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1dfd4519c022478b94e3b3e70da8965d |z Connect to this object online. |